Skip to main content
AbbViePatent grant

AbbVie was granted a patent for improved risankizumab compositions.

Source: Autobound Signal API · 112 signals tracked for AbbVie · updated

Get AbbVie's live signals in Claude or ChatGPT, or by API

AskWhat changed at AbbVie this week? Use Autobound signals for abbvie.com.

What happened

In November 2026 AbbVie patented risankizumab formulations for pharmaceutical use, designed to reduce unwanted proteins, processing additives, and immune reactions.

Source

patents.google.comNov 17, 2026

US patent US12799192

Risankizumab compositions

Abstract

The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.

patents.google.com/patent/US12799192Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 17, 2026
Inventors
Liqiang Zhou
Patent number
US12799192
Assignee
ABBVIE INC.

The full record

From the Signal API record

People

  • Liqiang ZhouInventor

Details

Primary CPC class
C07K 16/244
USPTO assignee
ABBVIE INC.
What the invention does
A formulation of risankizumab made with fewer unwanted protein contaminants and additives to help reduce the chance of an immune response.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • risankizumab
  • antibody formulations
  • biopharmaceutical manufacturing

Extraction

Detected
Nov 18, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for AbbVie and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b227c98d-06c0-5b28-8f85-0b30a7d0c9d5 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.

{
  "signal_id": "b227c98d-06c0-5b28-8f85-0b30a7d0c9d5",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-18T15:07:43+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07K 16/244"
      },
      {
        "code": "A61K 9/0019"
      },
      {
        "code": "A61K 9/08"
      },
      {
        "code": "A61K 38/465"
      },
      {
        "code": "A61K 39/3955"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In November 2026 AbbVie patented risankizumab formulations for pharmaceutical use, designed to reduce unwanted proteins, processing additives, and immune reactions.",
    "summary": "AbbVie was granted a patent for improved risankizumab compositions.",
    "event_at": "2026-11-17",
    "inventors": [
      {
        "name": "Liqiang Zhou",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/liqiang-lisa-zhou-166a6b32"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-17",
    "source_url": "https://patents.google.com/patent/US12799192",
    "cpc_primary": {
      "code": "C07K 16/244"
    },
    "patent_title": "Risankizumab compositions",
    "patent_number": "US12799192",
    "uspto_assignee": "ABBVIE INC.",
    "patent_abstract": "The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.",
    "precision_class": "structural",
    "invention_explanation": "A formulation of risankizumab made with fewer unwanted protein contaminants and additives to help reduce the chance of an immune response.",
    "technologies_mentioned": [
      "risankizumab",
      "antibody formulations",
      "biopharmaceutical manufacturing"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.